Evidence map›Paper›PMID 40106574›Full record

ArticleScience advances2025

Genome-wide CRISPR screen identifies IRF1 and TFAP4 as transcriptional regulators of Galectin-9 in T cell acute lymphoblastic leukemia.

Caroline R M Wiggers, Burak Yüzügüldü, Nathanial G Tadros, Tayla B Heavican-Foral, Eugene Y Cho, Zachary C Eisenbies, Merve Ozdemir, Steffen B Kulp, Yun-Cheol Chae, Alejandro Gutierrez and 2 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Caroline R M WiggersDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6633-1468
Burak YüzügüldüDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-2398-5389
Nathanial G TadrosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0009-9516-1942
Tayla B Heavican-ForalDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8384-6217
Eugene Y ChoDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1250-2932
Zachary C EisenbiesDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Merve OzdemirDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0009-6825-6305
Steffen B KulpDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0001-9400-690X
Yun-Cheol ChaeDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Alejandro GutierrezDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-0249-9007
Jens G LohrHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-3486-2445
Birgit KnoechelDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8040-0535

Funding

Targeting oncogenic TCR signaling in PTCLP01CA233412 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2019 to 2023
$8.7M
Discovery and targeting of apoptosis resistance mechanisms in high-risk T-ALLR01CA193651 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GUTIERREZ, ALEJANDRO · 2015 to 2024
$4.4M
Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal CancerR01CA249678 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GUTIERREZ, ALEJANDRO · 2021 to 2025
$3.2M
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implicationsR01CA249185 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KNOECHEL, BIRGIT · 2021 to 2025
$1.9M
Liquid Biopsy in Myeloma to Inform Outcome and Treatment DecisionsR37CA276044 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jens G Lohr · 2023 to 2026
$1.5M
NCI NIH HHS P01 CA233412NCI NIH HHS R01 CA193651NCI NIH HHS R01 CA249185NCI NIH HHS R01 CA249678NCI NIH HHS R37 CA276044
6 · The paper itself

Abstract

Galectin-9 is overexpressed in a variety of cancers and associated with worse clinical outcome in some cancers. However, the regulators driving Galectin-9 expression are unknown. Here, we defined the transcriptional regulators and epigenetic circuitry of Galectin-9 in pediatric T cell acute lymphoblastic leukemia (T-ALL), as an example of a disease with strong Galectin-9 expression, in which higher expression was associated with lower overall survival. By performing a genome-wide CRISPR screen, we identified the transcription factors IRF1 and TFAP4 as key regulators for Galectin-9 expression by binding its regulatory elements. Whereas IRF1 was observed exclusively on the promoter, TFAP4 binding was detected at an enhancer solely in T-ALL cells associated with higher Galectin-9 levels. Together, our results show that IRF1 is responsible and indispensable for Galectin-9 expression and TFAP4 further fine-tunes its expression. Our approach, a flow-based genome-wide CRISPR screen complemented by transcription factor binding and enhancer mapping, creates innovative opportunities for understanding and manipulating epigenetic transcriptional regulation in cancer.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsGalectinsGene Expression Regulation, LeukemicInterferon Regulatory Factor-1Precursor T-Cell Lymphoblastic Leukemia-LymphomaTranscription FactorsCell Line, TumorEnhancer Elements, GeneticEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansPromoter Regions, GeneticProtein BindingGalectinsInterferon Regulatory Factor-1IRF1 protein, humanLGALS9 protein, humanTranscription Factors

Identifiers

PMID40106574
PMCPMC11922064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.